3C Therapeutics is a Vancouver-based biotechnology company developing next-generation Degrader-Antibody Conjugates (DACs) — a new class of targeted therapeutics that harness the precision of antibodies to deliver protein degraders directly to diseased cells.

Our proprietary TriCore™ platform enables modular design and rapid optimization of DACs across multiple disease areas, extending the reach of targeted protein degradation beyond oncology. By integrating deep expertise in antibody engineering, linker chemistry, and protein degradation biology, 3C is building a versatile pipeline of disease-specific therapeutics with the potential for first-in-class activity.

We are advancing strategic collaborations with academic and industry partners to accelerate DAC innovation and bring powerful new treatment modalities to patients.

3C Therapeutics

Org chart

Teams

Offices

3C Therapeutics

Org chart

Teams

Offices

Related companies